Actively Recruiting
The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture
Led by Zhejiang Chinese Medical University · Updated on 2025-04-06
124
Participants Needed
1
Research Sites
76 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.
CONDITIONS
Official Title
The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 80 years
- Diagnosed with postherpetic neuralgia based on 2016 Chinese Expert Consensus criteria
- History of herpes zoster on the head and face with healed lesions
- Neuralgia symptoms lasting at least 1 month after lesion healing
- Baseline Facial Pain Profile score of 4 or higher
- Abnormal sensation and pain sensitivity around the lesion area
- Conscious and able to clearly sense and discriminate pain
- Signed informed consent to participate voluntarily
You will not qualify if you...
- Does not meet diagnostic criteria for postherpetic neuralgia
- Herpes zoster affecting the perineum or special types such as visceral, meningeal, or generalized herpes zoster
- Taking oral pregabalin at doses less than 0.2 g or more than 0.6 g daily before enrollment
- History of serious adverse reaction to pregabalin or allergy to acupuncture
- Contraindications to electroacupuncture
- Severe heart, liver, or kidney damage, epilepsy, head injury, cognitive dysfunction, aphasia, psychiatric disorders
- Poorly controlled hypertension or diabetes mellitus
- Pregnant or breastfeeding
- Currently participating in other studies or enrolled in another clinical trial within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiaoyu Li
Hangzhou, Zhejiang, China, 310053
Actively Recruiting
Research Team
X
Xiaoyu Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here